Zobrazeno 1 - 3
of 3
pro vyhledávání: '"T. Cso˝szi"'
Autor:
Martin Šmakal, T. Höhler, E. Van Cutsem, Elena Elez, J. Straub, Sonia Quaratino, Rolf Bruns, T. Cso˝szi, J. Tabernero, Sergei Tjulandin, Carsten Bokemeyer, Eldar Topuzov, Rashida Orlova, Uwe M. Martens, Bohuslav Melichar, Fernando Rivera, Ilona Kocáková
Publikováno v:
Annals of Oncology. 25:iv171
Aim: Abituzumab (EMD 525797, DI17E6) is a humanized monoclonal IgG2 antibody specifically targeting the an subunit of integrin receptors. POSEIDON is a Phase I/II open-label, randomized, controlled, multicenter trial (NCT01008475). Abituzumab ≤1000
Autor:
Andrea Pirzkall, Lori J. Wirth, T. Cso˝szi, Danny Rischin, Jan B. Vermorken, Cristina Oprean, Amy V. Kapp, Maria Anderson, Antonio Jimeno, Jérôme Fayette, Christopher M. Nutting, Ricardo Hitt, Elicia Penuel, X. Wang, Paul M. Harari, Bruce McCall, D. Cernea, A. Udrea
Publikováno v:
Annals of Oncology. 25:iv340
Aim: MEHD, a novel dual-action humanized IgG1 antibody that blocks ligand binding to EGFR and HER3, inhibits signaling from all ligand-dependent HER dimers, and can elicit antibody dependent cell mediated cytotoxicity. MEHD is active in multiple tumo
Autor:
Elena Elez, J. Straub, Rolf Bruns, Bohuslav Melichar, Rashida Orlova, T. Cso˝szi, Carsten Bokemeyer, Sergei Tjulandin, J. Tabernero, D. Vyushkov, E. Van Cutsem, Eldar Topuzov, Uwe M. Martens, Martin Šmakal, Fernando Rivera, Ilona Kocáková, T. Höhler, Sonia Quaratino
Publikováno v:
Annals of Oncology. 25:ii107